Leerink Partnrs Has Positive Outlook for ASND Q1 Earnings

Ascendis Pharma A/S (NASDAQ:ASND) – Equities researchers at Leerink Partnrs lifted their Q1 2025 EPS estimates for Ascendis Pharma A/S in a research report issued to clients and investors on Wednesday, February 12th. Leerink Partnrs analyst J. Schwartz now expects that the biotechnology company will earn ($1.63) per share for the quarter, up from their previous estimate of ($1.90). The consensus estimate for Ascendis Pharma A/S’s current full-year earnings is ($7.12) per share. Leerink Partnrs also issued estimates for Ascendis Pharma A/S’s Q2 2025 earnings at ($1.44) EPS, Q3 2025 earnings at ($1.39) EPS, Q4 2025 earnings at ($1.45) EPS, FY2025 earnings at ($5.91) EPS and FY2026 earnings at ($2.28) EPS.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($1.32) by $0.64.

ASND has been the topic of several other reports. UBS Group initiated coverage on shares of Ascendis Pharma A/S in a research report on Tuesday, January 7th. They set a “buy” rating and a $196.00 price target on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $170.00 price target on shares of Ascendis Pharma A/S in a research report on Tuesday, February 11th. The Goldman Sachs Group upped their price target on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a “buy” rating in a research report on Thursday, February 13th. Oppenheimer dropped their price target on shares of Ascendis Pharma A/S from $190.00 to $180.00 and set an “outperform” rating on the stock in a research report on Friday, November 15th. Finally, Evercore ISI upped their price target on shares of Ascendis Pharma A/S from $220.00 to $260.00 and gave the stock an “outperform” rating in a research report on Tuesday. Two investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $197.36.

Ascendis Pharma A/S Trading Up 9.1 %

NASDAQ ASND opened at $157.17 on Monday. The firm’s fifty day moving average price is $133.20 and its two-hundred day moving average price is $132.57. Ascendis Pharma A/S has a 1 year low of $111.09 and a 1 year high of $161.00. The firm has a market capitalization of $9.54 billion, a P/E ratio of -19.45 and a beta of 0.64.

Hedge Funds Weigh In On Ascendis Pharma A/S

Several institutional investors and hedge funds have recently modified their holdings of the business. Signaturefd LLC grew its stake in shares of Ascendis Pharma A/S by 13.2% in the third quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock valued at $102,000 after acquiring an additional 80 shares in the last quarter. Virtus ETF Advisers LLC grew its stake in shares of Ascendis Pharma A/S by 3.9% in the fourth quarter. Virtus ETF Advisers LLC now owns 2,676 shares of the biotechnology company’s stock valued at $368,000 after acquiring an additional 100 shares in the last quarter. Legato Capital Management LLC grew its stake in shares of Ascendis Pharma A/S by 7.5% in the fourth quarter. Legato Capital Management LLC now owns 1,921 shares of the biotechnology company’s stock valued at $264,000 after acquiring an additional 134 shares in the last quarter. Jones Financial Companies Lllp grew its stake in shares of Ascendis Pharma A/S by 394.0% in the fourth quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company’s stock valued at $34,000 after acquiring an additional 197 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Ascendis Pharma A/S in the fourth quarter valued at about $28,000.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.